Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity (Nature Communications, (2016), 7, 1, (10787), 10.1038/ncomms10787);Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Sant'Anna, Ricardo ^a   Gallego, Pablo ^a   Robinson, Lei Z ^b   Pereira Henriques, Alda ^c   Ferreira, Nelson ^c   Pinheiro, Francisca ^a   Esperante, Sebastian ^a   Pallares, Irantzu ^a   Huertas, Oscar ^d   Almeida, Maria Rosário ^c   Reixach, Natàlia ^b   Insa, Raul ^d   Velazquez Campoy, Adrian ^e,f,g   Reverter, David ^a   Reig, Núria ^d   Ventura, Salvador ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PORTO   (Portugal)

^d SOM Biotech   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^g FUNDACIÓN ARAID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN; TAFAMIDIS; TETRAMER; TOLCAPONE; BENZOPHENONE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; NITROPHENOL;

AGGREGATION; CELLS AND CELL COMPONENTS; DISEASE; DRUG; INHIBITOR; NERVOUS SYSTEM DISORDER; PLASMA; PROTEIN; RODENT; TOXICITY;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CARDIOMYOPATHY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG PROTEIN BINDING; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARKINSON DISEASE; PROTEIN STABILITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; AMYLOID NEUROPATHIES, FAMILIAL; ANIMAL; CELL LINE; DIMERIZATION; DRUG EFFECTS; DRUG REPOSITIONING; METABOLISM; MIDDLE AGED; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROTEIN AGGREGATION, PATHOLOGICAL; TRANSGENIC MOUSE;

MUS;

ADMINISTRATION, ORAL; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CELL LINE; DIMERIZATION; DRUG REPOSITIONING; HEALTHY VOLUNTEERS; HUMANS; MICE, TRANSGENIC; MIDDLE AGED; NITROPHENOLS; PREALBUMIN; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84959087061     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-023-36239-z     Document Type: Erratum

References (64)

1. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366 (2006).
2. Cornwell, 3rd G. G., Sletten, K., Johansson, B. & Westermark, P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem. Biophys. Res. Commun. 154, 648-653 (1988).
3. Westermark, P., Sletten, K., Johansson, B. & Cornwell, 3rd G. G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl Acad. Sci. USA 87, 2843-2845 (1990).
4. Rapezzi, C. et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat. Rev. Cardiol. 7, 398-408 (2010).
5. Hou, X., Aguilar, M. I. & Small, D. H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 274, 1637-1650 (2007).
6. Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T. & Kelly, J. W. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 421, 185-203 (2012).
7. Goren, H., Steinberg, M. C. & Farboody, G. H. Familial oculoleptomeningeal amyloidosis. Brain 103, 473-495 (1980).
8. Sekijima, Y. et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab. Invest. 83, 409-417 (2003).
9. Azevedo, E. P. et al. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid. Biochemistry 50, 11070-11083 (2011).
10. Bartalena, L. & Robbins, J. Thyroid hormone transport proteins. Clin. Lab. Med. 13, 583-598 (1993).
11. Hornberg, A., Eneqvist, T., Olofsson, A., Lundgren, E. & Sauer-Eriksson, A. E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 302, 649-669 (2000).
12. Hamilton, J. A. & Benson, M. D. Transthyretin: a review from a structural perspective. Cell. Mol. Life. Sci. 58, 1491-1521 (2001).
13. Jiang, X. et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40, 11442-11452 (2001).
14. Quintas, A., Vaz, D. C., Cardoso, I., Saraiva, M. J. & Brito, R. M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276, 27207-27213 (2001).
15. Hammarstrom, P., Jiang, X., Hurshman, A. R., Powers, E. T. & Kelly, J. W. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl Acad. Sci. USA 99(Suppl 4): 16427-16432 (2002).
16. Sekijima, Y. et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85 (2005).
17. Herlenius, G., Wilczek, H. E., Larsson, M. & Ericzon, B. G. Familial amyloidotic polyneuropathy world transplant R. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 77, 64-71 (2004).
18. Johnson, S. M. et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911-921 (2005).
19. Miller, S. R., Sekijima, Y. & Kelly, J. W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab. Invest. 84, 545-552 (2004).
20. Tojo, K., Sekijima, Y., Kelly, J. W. & Ikeda, S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci. Res. 56, 441-449 (2006).
21. Baures, P. W., Oza, V. B., Peterson, S. A. & Kelly, J. W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 7, 1339-1347 (1999).
22. Klabunde, T. et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 7, 312-321 (2000).
23. Cardoso, I., Merlini, G. & Saraiva, M. J. 4′-Iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 17, 803-809 (2003).
24. Wiseman, R. L. et al. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc. 127, 5540-5551 (2005).
25. Johnson, S. M., Connelly, S., Wilson, I. A. & Kelly, J. W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 51, 6348-6358 (2008).
26. Oza, V. B. et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 45, 321-332 (2002).
27. Razavi, H. et al. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg. Med. Chem. Lett. 15, 1075-1078 (2005).
28. Johnson, S. M., Connelly, S., Wilson, I. A. & Kelly, J. W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J. Med. Chem. 51, 260-270 (2008).
29. Bulawa, C. E. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA 109, 9629-9634 (2012).
30. Merkies, I. S. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 80, 1444-1445 (2013).
31. Lozeron, P. et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur. J. Neurol. 20, 1539-1545 (2013).
32. Li, Y. Y. & Jones, S. J. Drug repositioning for personalized medicine. Genome Med. 4, 27 (2012).
33. Sekijima, Y., Dendle, M. A. & Kelly, J. W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13, 236-249 (2006).
34. Adamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C. & Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 47, 355-374 (2004).
35. Berk, J. L. et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310, 2658-2667 (2013).
36. Dolado, I. et al. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J. Comb. Chem. 7, 246-252 (2005).
37. Jiang, X., Buxbaum, J. N. & Kelly, J. W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA 98, 14943-14948 (2001).
38. Zhao, L., Buxbaum, J. N. & Reixach, N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52, 1913-1926 (2013).
39. Robinson, L. Z. & Reixach, N. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case. Biochemistry 53, 6496-6510 (2014).
40. Jorga, K. M. et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 62, 300-310 (1997).
41. Hurshman, A. R., White, J. T., Powers, E. T. & Kelly, J. W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43, 7365-7381 (2004).
42. Almeida, M. R. et al. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 381, 351-356 (2004).
43. Freire, E., Schon, A. & Velazquez-Campoy, A. Isothermal titration calorimetry: general formalism using binding polynomials. Methods Enzymol. 455, 127-155 (2009).
44. Vega, S., Abian, O. & Velazquez-Campoy, A. A unified framework based on the binding polynomial for characterizing biological systems by isothermal titration calorimetry. Methods 76, 99-115 (2015).
45. Penchala, S. C. et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl Acad. Sci. USA 110, 9992-9997 (2013).
46. Davidson, M. M. et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39, 133-147 (2005).
47. Bourgault, S. et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Co. 410, 707-713 (2011).
48. Manral, P. & Reixach, N. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci. Rep. 35, e00172 (2015).
49. Ferreira, N., Saraiva, M. J. & Almeida, M. R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett. 585, 2424-2430 (2011).
50. Lashuel, H. A., Wurth, C., Woo, L. & Kelly, J. W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38, 13560-13573 (1999).
51. Cardoso, I. et al. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem. J. 408, 131-138 (2007).
52. Nagata, Y. et al. A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse. J. Biochem. 117, 169-175 (1995).
53. Pahwa, R. & Lyons, K. E. Handbook of Parkinson's Disease, Fifth Edition (CRC Press, 2013).
54. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
55. Page, J. & Henry, D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch. Intern. Med. 160, 777-784 (2000).
56. Wallace, J. L. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract. Res. Clin. Gastroenterol. 15, 691-703 (2001).
57. Chanoine, J. P. et al. Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain. Endocrinology 130, 933-938 (1992).
58. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002).
59. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W. & Buxbaum, J. N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl Acad. Sci. USA 101, 2817-2822 (2004).
60. Saraiva, M. J. Transthyretin mutations in health and disease. Hum. Mutat. 5, 191-196 (1995).
61. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13, 869-874 (2008).
62. Ferreira, N. et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 583, 3569-3576 (2009).
63. Heizmann, P., Schmitt, M., Leube, J., Martin, H. & Saner, A. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl. 730, 153-160 (1999).
64. Sun, J., Von Tungeln, L. S., Hines, W. & Beger, R. D. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 2557-2565 (2009).